Becton, Dickinson and Company announced the launch of the HemoSphere Stream Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinicians close gaps between intermittent readings. The compact HemoSphere Stream Module mounts easily to an IV pole, taking no additional footprint in clinical environments.
When used with the VitaWave Plus Finger Cuff, the HemoSphere Stream Module serves as the interface that delivers continuous, noninvasive arterial blood pressure waveform data to compatible multiparameter monitors. Together with the finger cuff and supporting accessories, it comprises the VitaWave Plus System, which is designed for accuracy using technology validated against arterial line measurements. Continuous blood pressure helps reveal hemodynamic changes that may occur between intermittent blood pressure checks, which are typically taken every 3?5 minutes in the operating room.
By providing a real-time view into blood pressure trends on any compatible patient monitor, the VitaWave Plus System supports the Anesthesia Patient Safety Foundation's recommendations for continuous noninvasive hemodynamic monitoring to detect and treat intraoperative hypotension sooner.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.;
- interventional medical equipment (23.9%): surgical instruments, urological care products, etc.;
- diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.